Initiation of Antipsychotics During the First Year After First‐Episode Psychosis: A Population‐Based Study.
Saved in:
| Title: | Initiation of Antipsychotics During the First Year After First‐Episode Psychosis: A Population‐Based Study. |
|---|---|
| Authors: | Odsbu, I. (AUTHOR), Hamina, A. (AUTHOR), Hjellvik, V. (AUTHOR), Handal, M. (AUTHOR), Haram, M. (AUTHOR), Tesli, M. (AUTHOR), Tanskanen, A. (AUTHOR), Taipale, H. (AUTHOR) |
| Source: | Acta Psychiatrica Scandinavica. Apr2025, Vol. 151 Issue 4, p537-547. 11p. |
| Subjects: | Drug utilization, Drugs, Poisson regression, Secondary care (Medicine), Anxiety disorders |
| Abstract: | Background: Antipsychotics are recommended after first‐episode psychosis. Knowledge on the current use patterns in real‐world settings is thus important to inform clinical practice. We aimed to describe antipsychotic initiation during 1 year after first‐episode psychosis and its associated factors. Methods: Population‐based cohort study using linked nationwide health and population registers from Norway. The study population comprised 8052 persons aged 16–45 years with first‐episode psychosis diagnosed in secondary care (ICD‐10 F20, F22–F29) in the period 2011–2019. Initiation of antipsychotic use was defined as being dispensed antipsychotics (ATC N05A, excl. lithium) at least once from −90 to +365 days from secondary care diagnosis of first‐episode psychosis. Antipsychotic polypharmacy during follow‐up was defined as having at least 90 days with overlapping drug use periods modeled using the Prescriptions to Drug Use Periods method. Adjusted risk ratios (aRRs) with 95% confidence intervals (CIs) for the association between socioeconomic and clinical factors and initiation of antipsychotic use were calculated using modified Poisson regression. Results: In total, 4413 persons (54.8%) initiated antipsychotic use after first‐episode psychosis with proportions ranging from 45.5% in 2012 to 62.1% in 2019. Oral formulations of olanzapine (34.9%), quetiapine (21.2%), and aripiprazole (11.6%) were most common at initiation, whereas long‐acting injectables (LAIs) and clozapine were rarely used. Among the initiators, 13.8% started a polypharmacy period lasting more than 90 days. Factors associated with antipsychotic initiation were lower age (aRR 1.14, 95% CI 1.08–1.21; 26–35 years vs. 36–45 years), higher education (1.11, 1.05–1.18), being employed (1.04, 1.00–1.09), being hospitalized (1.13, 1.09–1.18), being diagnosed late in the study period (1.16, 1.11–1.22; 2017–2019 vs. 2011–2013), or with previously diagnosed bipolar disorder, depression, or anxiety disorders. Conclusions: The antipsychotic use pattern is largely within the current clinical guideline. Primary non‐compliance and disease severity may explain the socioeconomic and clinical differences related to initiation of antipsychotic use. [ABSTRACT FROM AUTHOR] |
| Copyright of Acta Psychiatrica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background: Antipsychotics are recommended after first‐episode psychosis. Knowledge on the current use patterns in real‐world settings is thus important to inform clinical practice. We aimed to describe antipsychotic initiation during 1 year after first‐episode psychosis and its associated factors. Methods: Population‐based cohort study using linked nationwide health and population registers from Norway. The study population comprised 8052 persons aged 16–45 years with first‐episode psychosis diagnosed in secondary care (ICD‐10 F20, F22–F29) in the period 2011–2019. Initiation of antipsychotic use was defined as being dispensed antipsychotics (ATC N05A, excl. lithium) at least once from −90 to +365 days from secondary care diagnosis of first‐episode psychosis. Antipsychotic polypharmacy during follow‐up was defined as having at least 90 days with overlapping drug use periods modeled using the Prescriptions to Drug Use Periods method. Adjusted risk ratios (aRRs) with 95% confidence intervals (CIs) for the association between socioeconomic and clinical factors and initiation of antipsychotic use were calculated using modified Poisson regression. Results: In total, 4413 persons (54.8%) initiated antipsychotic use after first‐episode psychosis with proportions ranging from 45.5% in 2012 to 62.1% in 2019. Oral formulations of olanzapine (34.9%), quetiapine (21.2%), and aripiprazole (11.6%) were most common at initiation, whereas long‐acting injectables (LAIs) and clozapine were rarely used. Among the initiators, 13.8% started a polypharmacy period lasting more than 90 days. Factors associated with antipsychotic initiation were lower age (aRR 1.14, 95% CI 1.08–1.21; 26–35 years vs. 36–45 years), higher education (1.11, 1.05–1.18), being employed (1.04, 1.00–1.09), being hospitalized (1.13, 1.09–1.18), being diagnosed late in the study period (1.16, 1.11–1.22; 2017–2019 vs. 2011–2013), or with previously diagnosed bipolar disorder, depression, or anxiety disorders. Conclusions: The antipsychotic use pattern is largely within the current clinical guideline. Primary non‐compliance and disease severity may explain the socioeconomic and clinical differences related to initiation of antipsychotic use. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 0001690X |
| DOI: | 10.1111/acps.13776 |
